Analysis of Profitability Ratios
Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
AstraZeneca PLC, profitability ratios
Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | AstraZeneca PLC gross profit margin ratio deteriorated from 2012 to 2013 and from 2013 to 2014. |
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | AstraZeneca PLC operating profit margin ratio deteriorated from 2012 to 2013 and from 2013 to 2014. |
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | AstraZeneca PLC net profit margin ratio deteriorated from 2012 to 2013 and from 2013 to 2014. |
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | AstraZeneca PLC ROE deteriorated from 2012 to 2013 and from 2013 to 2014. |
| ROA | A profitability ratio calculated as net income divided by total assets. | AstraZeneca PLC ROA deteriorated from 2012 to 2013 and from 2013 to 2014. |
Gross Profit Margin
AstraZeneca PLC, gross profit margin calculation, comparison to benchmarks
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Gross profit | 20,253) | 20,450) | 22,580) | 27,565) | 26,880) | |
| Revenue | 26,095) | 25,711) | 27,973) | 33,591) | 33,269) | |
| Profitability Ratio | ||||||
| Gross profit margin1 | 77.61% | 79.54% | 80.72% | 82.06% | 80.80% | |
| Benchmarks | ||||||
| Gross Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Zoetis Inc. | — | — | — | — | — | |
Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).
1 2014 Calculation
Gross profit margin = 100 × Gross profit ÷ Revenue
= 100 × 20,253 ÷ 26,095 = 77.61%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | AstraZeneca PLC gross profit margin ratio deteriorated from 2012 to 2013 and from 2013 to 2014. |
Operating Profit Margin
AstraZeneca PLC, operating profit margin calculation, comparison to benchmarks
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Operating profit | 2,137) | 3,712) | 8,148) | 12,795) | 11,494) | |
| Revenue | 26,095) | 25,711) | 27,973) | 33,591) | 33,269) | |
| Profitability Ratio | ||||||
| Operating profit margin1 | 8.19% | 14.44% | 29.13% | 38.09% | 34.55% | |
| Benchmarks | ||||||
| Operating Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Zoetis Inc. | — | — | — | — | — | |
Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).
1 2014 Calculation
Operating profit margin = 100 × Operating profit ÷ Revenue
= 100 × 2,137 ÷ 26,095 = 8.19%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | AstraZeneca PLC operating profit margin ratio deteriorated from 2012 to 2013 and from 2013 to 2014. |
Net Profit Margin
AstraZeneca PLC, net profit margin calculation, comparison to benchmarks
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Profit attributable to owners of the Parent | 1,233) | 2,556) | 6,297) | 9,983) | 8,053) | |
| Revenue | 26,095) | 25,711) | 27,973) | 33,591) | 33,269) | |
| Profitability Ratio | ||||||
| Net profit margin1 | 4.73% | 9.94% | 22.51% | 29.72% | 24.21% | |
| Benchmarks | ||||||
| Net Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Zoetis Inc. | — | — | — | — | — | |
Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).
1 2014 Calculation
Net profit margin = 100 × Profit attributable to owners of the Parent ÷ Revenue
= 100 × 1,233 ÷ 26,095 = 4.73%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | AstraZeneca PLC net profit margin ratio deteriorated from 2012 to 2013 and from 2013 to 2014. |
Return on Equity (ROE)
AstraZeneca PLC, ROE calculation, comparison to benchmarks
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Profit attributable to owners of the Parent | 1,233) | 2,556) | 6,297) | 9,983) | 8,053) | |
| Capital and reserves attributable to equity holders of the Company | 19,627) | 23,224) | 23,737) | 23,246) | 23,213) | |
| Profitability Ratio | ||||||
| ROE1 | 6.28% | 11.01% | 26.53% | 42.95% | 34.69% | |
| Benchmarks | ||||||
| ROE, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Zoetis Inc. | — | — | — | — | — | |
Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).
1 2014 Calculation
ROE = 100 × Profit attributable to owners of the Parent ÷ Capital and reserves attributable to equity holders of the Company
= 100 × 1,233 ÷ 19,627 = 6.28%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | AstraZeneca PLC ROE deteriorated from 2012 to 2013 and from 2013 to 2014. |
Return on Assets (ROA)
AstraZeneca PLC, ROA calculation, comparison to benchmarks
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Profit attributable to owners of the Parent | 1,233) | 2,556) | 6,297) | 9,983) | 8,053) | |
| Total assets | 58,595) | 55,899) | 53,534) | 52,830) | 56,127) | |
| Profitability Ratio | ||||||
| ROA1 | 2.10% | 4.57% | 11.76% | 18.90% | 14.35% | |
| Benchmarks | ||||||
| ROA, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Zoetis Inc. | — | — | — | — | — | |
Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).
1 2014 Calculation
ROA = 100 × Profit attributable to owners of the Parent ÷ Total assets
= 100 × 1,233 ÷ 58,595 = 2.10%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROA | A profitability ratio calculated as net income divided by total assets. | AstraZeneca PLC ROA deteriorated from 2012 to 2013 and from 2013 to 2014. |